Mesothelioma website posts encouraging news about mesothelioma

mesotheliomaMesothelioma.us, a free online resource filled with helpful information for people who have been diagnosed with mesothelioma, is now reporting that mesothelioma is more beatable than previously believed.

As a spokesperson for http://www.mesothelioma.us/ noted, the website recently posted new information about clinical trials and treatments that may help the rare form of cancer that is caused by exposure to asbestos.

For example, the National Institute of Cancer is working tirelessly to research mesothelioma, its symptoms, diagnosis and treatment.

Also, new clinical trials are continually being introduced to the public, and there are many different types of treatments that are currently being used to treat mesothelioma, the spokesperson said.

In addition to posting new and encouraging news about mesothelioma whenever possible, the founders of Mesothelioma.us are devoted to helping people who have been diagnosed with the disease, as well as their loved ones. They understand how devastating it is to hear an oncologist say "I'm sorry, but you have mesothelioma" and work tirelessly to make sure their website is a place where people can go for the latest and most accurate information about the cancer.

"A lot of research on mesothelioma is devoted to learning about how asbestos affects cells, and how cells are changed by exposure to this material," the spokesperson for Mesothelioma.us noted, adding that with the knowledge gained from this research, scientists hope to learn how the disease can be prevented or minimized.

"Some good news is that there are many new trials being carried out on a regular basis, and with information and technology that is available today, the discovery of an effective treatment for mesothelioma patients is just a matter of time."

While there is still no "quick fix" to treating mesothelioma, the founders of Mesothelioma.us vow to continually update their website with the latest research and information about clinical trials.